![]() |
Market Research Report
Product code
1006078
Biologics Market with COVID-19 Impact Analysis, By Product, By Application, and By Region - Size, Share, & Forecast from 2021-2027 |
Biologics Market with COVID-19 Impact Analysis, By Product, By Application, and By Region - Size, Share, & Forecast from 2021-2027 |
Published: May 1, 2021
AnalystView Market Insights
Content info: 300 Pages
Delivery time: 2-3 business days
|
The global biologics market was valued at USD 330.6 billion by 2020, growing with 9.8% CAGR during the forecast period, 2021-2027.
Biologics are medicines that are made up of genetically modified proteins derived from human genes. It could also be made up of proteins, sugars, nucleic acids, or complex combinations of these compounds, or living organisms like tissues and cells, according to the US FDA. The majority of biologics are complex mixtures that are prone to microbial contamination, heat-sensitive, difficult to classify or identify. Increasing government healthcare initiatives, rising availability of advanced diagnostics, and growing technological advances in research and development by major drug companies around the world to maintain competitiveness and investment in incremental innovation would drive biologics market growth during the forecast era.
Rising cancer diseases amongst the people have boosted the need for biologics. Biologic drugs have the ability to stimulate the body and spot cancer cells and attack them. According to the International Agency for Research on Cancer (IARC), 17.0 Mn new cancer cases and 9.5 Mn cancer deaths occurred globally in 2018. Simply due to population growth and aging, the global burden of cancer is projected to rise to 27.5 Mn new cases and 16.3 Mn cancer deaths by 2040. In economically transitioning nations, the potential burden would almost certainly be greater due to a rise in the prevalence of risk factors such as poor diet, smoking, fewer childbirths, and physical inactivity. Hence, such factors will lead to increasing the adoption of biologics drugs for the treatment of cancer. Furthermore, increasing technological advancement and research & development activities will also promote market growth. However, high complex nature of biologics causes difficulties in manufacturing. Hence, this acts as a restrain for the biologics market growth.
Based on the product analysis, the biologics market is categorized into monoclonal antibodies, vaccines, recombinant hormones/proteins, cellular-based biologics, and gene-based biologics. The monoclonal antibodies segment is anticipated to witness the highest growth during the forecast timeline. The growth is associated with the treatment of autoimmune diseases including rheumatoid arthritis and cancer management. The rising spread of contagious disease coupled with the increasing advancement of drugs will propel the vaccine segment growth. Based on application, the cancer segment holds the highest market share, due to the growing prevalence of cancer across the globe. Furthermore, an increasing product advancement will also contribute to boosting the demand for biologics during the forecasted era.
In the global market, North America accounted to witness the highest growth during the forecast period. The greater revenue share can be attributed to a higher demand for disease-treatment drugs. Furthermore, pharmaceutical firms in the United States are responsible for the highest market share of global R&D in healthcare biotechnology.
Due to the rising prevalence of diabetes in the Asia Pacific, this region is projected to be the fastest-growing region in the global biologics market. According to the International Diabetes Federation (IDF) Diabetes Atlas 2017, the number of people with diabetes aged 20 to 79 years in the Western Pacific regions and South East Asia in 2017 was 159 million and 82 million, respectively, according to the International Diabetes Federation (IDF). The increase in the aging population, changing lifestyles, and shifting purchasing habits on healthcare goods have all contributed to the biologics market expansion in Europe. The Middle East & Africa is anticipated to grow with sustainable growth owing to the rising adoption of recombinant protein in various applications.
Key features of the study:
This proposed research study on biologics market provides market size (US$ million), compound annual growth rate (CAGR %) and forecast estimation (2020-2027), considering 2019 as the base year
The research report elucidates potential growth opportunities across different segments/countries and explains attractive investment proposition matrix for biologics market
The overall report identifies new investment opportunities, challenges faced by established players, and growth factors to sustain in the biologics market
Impact of COVID-19 on biologics market size, forecast, CAGR, and market dynamics are discussed in detail under the research scope. Detailed insight on biologics market post-COVID will also be covered.
In order to give the users of this report a comprehensive view on the biologics market, we have also included competitive landscape and key innovator analysis for the biologics market.
The study encompasses a growth prospect mapping analysis, wherein all the industry segments are benchmarked based on their market size, growth rate and end-user's attractiveness.
The report offers detailed company profiling featuring major market participants which will help users to understand their financial information and strategic initiatives of players operating in the biologics market.
In addition, the report also unveil the important acquisitions & mergers, collaborations & joint ventures, new application launch, research & development, regional expansion of major participants involved in the biologics market on global as well as regional level.
The global biologics market report primarily caters to various stakeholders in this industry including suppliers, investors, new entrants, distributors, and financial analysts
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
GLOBAL BIOLOGICS MARKET KEY PLAYERS
Unilife Corporation
Retractable Technologies, Inc.
Smiths Medicals
Becton, Dickinson & Company
Smiths Medical
Terumo Corporation
Pfizer Inc.
Roche Diagnostics
AstraZeneca
Bayer AG
Genzyme
GSK Biologicals
Lundbeck
Novartis AG
Merck KGaA
Janssen Pharmaceuticals, Inc.
GLOBAL BIOLOGICS MARKET, BY PRODUCT
Monoclonal Antibodies
Vaccines
Recombinant Hormones/Proteins
Cellular-based Biologics
Gene-based Biologics
Other
GLOBAL BIOLOGICS MARKET, BY APPLICATION
Autoimmune Diseases
Cancer
Infectious Diseases
Rare Diseases
Others
GLOBAL BIOLOGICS MARKET, BY REGION
North America
The U.S.
Canada
Europe
Germany
France
Italy
Spain
United Kingdom
Rest of Europe
Asia Pacific
India
China
South Korea
Japan
Singapore
Rest of APAC
Latin America
Brazil
Mexico
Argentina
Rest of LATAM
The Middle East and Africa
Saudi Arabia
United Arab Emirates
Rest of MEA
List of Tables
List of Figures